ATE405655T1 - Obg3 globularekopf und seine verwendungen zur reduzierung des körpersgewichtes - Google Patents

Obg3 globularekopf und seine verwendungen zur reduzierung des körpersgewichtes

Info

Publication number
ATE405655T1
ATE405655T1 AT01942383T AT01942383T ATE405655T1 AT E405655 T1 ATE405655 T1 AT E405655T1 AT 01942383 T AT01942383 T AT 01942383T AT 01942383 T AT01942383 T AT 01942383T AT E405655 T1 ATE405655 T1 AT E405655T1
Authority
AT
Austria
Prior art keywords
obesity
reducing body
body weight
globular head
obg3
Prior art date
Application number
AT01942383T
Other languages
English (en)
Inventor
Bernard Bihain
Mary Erickson
Joachim Fruebis
Frances Yen-Potin
Original Assignee
Serono Genetics Inst Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Genetics Inst Sa filed Critical Serono Genetics Inst Sa
Application granted granted Critical
Publication of ATE405655T1 publication Critical patent/ATE405655T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
AT01942383T 2000-01-14 2001-01-10 Obg3 globularekopf und seine verwendungen zur reduzierung des körpersgewichtes ATE405655T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17622800P 2000-01-14 2000-01-14
US19808700P 2000-04-13 2000-04-13
US22988100P 2000-09-01 2000-09-01

Publications (1)

Publication Number Publication Date
ATE405655T1 true ATE405655T1 (de) 2008-09-15

Family

ID=27390648

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01942383T ATE405655T1 (de) 2000-01-14 2001-01-10 Obg3 globularekopf und seine verwendungen zur reduzierung des körpersgewichtes

Country Status (14)

Country Link
EP (1) EP1248849B1 (de)
JP (1) JP4698914B2 (de)
AT (1) ATE405655T1 (de)
AU (1) AU785090B2 (de)
BR (1) BR0107626A (de)
CA (1) CA2383136C (de)
CY (1) CY1108461T1 (de)
DE (1) DE60135439D1 (de)
DK (1) DK1248849T3 (de)
ES (1) ES2312450T3 (de)
IL (2) IL150554A0 (de)
MX (1) MXPA02006834A (de)
PT (1) PT1248849E (de)
WO (1) WO2001051645A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001092330A2 (en) * 2000-05-31 2001-12-06 Genset S.A. Use of acrp30 globular head to promote increases in muscle mass and muscle differentiation
WO2003009862A1 (en) * 2001-07-20 2003-02-06 Genset S.A. Agonists and antagonists of modumet for use in the treatment of metabolic disorders
WO2003009864A1 (en) * 2001-07-23 2003-02-06 Genset S.A. Agonists and antagonists of disomet for the treatment of metabolic disorders
WO2003009861A1 (en) * 2001-07-24 2003-02-06 Genset S.A. Agonists and antagonists of metabolix in the treatment of metabolic disorders
WO2003009865A1 (en) * 2001-07-25 2003-02-06 Genset S.A. Agonists and antagonists of energen for use in the treatment of metabolic disorders
WO2003009863A1 (en) * 2001-07-26 2003-02-06 Genset S.A. Agonists and antagonists of cofoxin for use in the treatment of metabolic disorders
WO2003011325A1 (en) * 2001-07-27 2003-02-13 Genset S.A. Agonists and antagonists of moceptin for the treatment of metabolic disorders
WO2003011323A1 (en) * 2001-07-30 2003-02-13 Genset S.A. Agonists and antagonists of contabix for use in the treatment of metabolic disorders
WO2003011321A1 (en) * 2001-07-31 2003-02-13 Genset S.A. Agonists and antagonists of cobesin for the treatment of metabolic disorders
WO2003011324A1 (en) * 2001-07-31 2003-02-13 Genset S.A. Agonists and antagonists of moxifin for the treatment of metabolic disorders
WO2003011318A1 (en) * 2001-08-01 2003-02-13 Genset S.A. Agonists and antagonists of famoset for use in the treatment of metabolic disorders
US20070129291A1 (en) * 2001-08-01 2007-06-07 Genset S.A. Genobix agonists and antagonists for use in the treatment of metabolic disorders
WO2003011320A1 (en) * 2001-08-02 2003-02-13 Genset S.A. Agonists and antagonists of obesingen for the treatment of metabolic disorders
WO2003011322A1 (en) * 2001-08-02 2003-02-13 Genset S.A. Agonists and antagonists of genoxin for use in the treatment of metabolic disorders
EP1418934A1 (de) * 2001-08-02 2004-05-19 Genset S.A. Agonisten und antagonisten von xobesin zur behandlung von stoffwechselerkrankungen
WO2003013579A1 (en) * 2001-08-03 2003-02-20 Genset S.A. Lypergix agonists and antagonists for use in the treatment of metabolic disorders
WO2003013581A1 (en) * 2001-08-03 2003-02-20 Genset S.A. Agonists and antagonists of genceptin for the treatment of metabolic disorders
WO2003013580A1 (en) * 2001-08-03 2003-02-20 Genset S.A. Tr xidatin agonists and antagonists treatment of metabolic disorders
WO2003013582A1 (en) * 2001-08-06 2003-02-20 Genset S.A. Genoxit agonists and antagonists for use in the treatment of metabolic disorders
WO2003013578A1 (en) * 2001-08-07 2003-02-20 Genset S.A. Omoxin agonists and antagonists for use in the treatment of metabolic disorders
WO2003013585A1 (en) * 2001-08-08 2003-02-20 Genset S.A. Mifaxin agonists and antagonists for use in the treatment of metabolic
WO2003013584A1 (en) * 2001-08-09 2003-02-20 Genset S.A. Xafinix agonists and antagonists for use in the treatment of metabolic disorders
AU2002339213A1 (en) * 2001-08-09 2003-02-24 Genset S.A. Migenix agonists and antagonists for use in the treatment of metabolic disorders
WO2003013583A1 (en) * 2001-08-10 2003-02-20 Genset S.A. Faxigen agonists and antagonists in the treatment of metabolic disorders
WO2003026695A1 (en) * 2001-09-21 2003-04-03 Genset S.A. Agonists and antagonists of cylixin for the treatment of metabolic disorders
JP4423038B2 (ja) 2001-10-05 2010-03-03 セローノ ジェネティクス インスティテュート ソシエテ アノニム Ｇｚｉｐポリヌクレオチドおよびポリペプチドならびにその使用
WO2003041730A1 (en) * 2001-11-16 2003-05-22 Genset S.A. Ditacin agonists and antagonists for use in the treatment of metabolic disorders
US20060089311A1 (en) * 2001-11-28 2006-04-27 Deno Dialvnas Agonists and antagonists of ryzn for the treatment of metabolic disorders
AU2002339691A1 (en) 2001-11-29 2003-06-10 Genset Agonists and antagonists of prolixin for the treatment of metabolic disorders
AU2002339683A1 (en) * 2001-12-05 2003-06-17 Genset S.A. Agonist and antagonists of redax for the treatment of metabolic disorders
AU2002339689A1 (en) * 2001-12-05 2003-06-17 Genset S.A. Dexar agonists and antagonists for use in the treatment of metabolic disorders
WO2003049757A1 (en) * 2001-12-12 2003-06-19 Genset S.A. Agonists and antagonists of glucomin for the treatment of metabolic disorders
WO2003049758A1 (en) * 2001-12-13 2003-06-19 Genset S.A. Emergen agonists and antagonists for use in the treatment of metabolic disorders
WO2003049759A1 (en) * 2001-12-13 2003-06-19 Genset S.A. Agonists and antagonists of oxifan for the treatment of metabolic disorders
AU2002339679A1 (en) * 2001-12-13 2003-06-23 Genset S.A. Glucomin agonists and antagonists for use in the treatment of metabolic disorders
AU2002339688A1 (en) * 2001-12-14 2003-06-30 Genset S.A. Glucoset agonists and antagonists for use in the treatment of metabolic disorders
EP1458758A2 (de) * 2001-12-21 2004-09-22 Maxygen Aps Adiponectin-fragmente und -konjugate
WO2003055509A1 (en) * 2001-12-26 2003-07-10 Genset S.A. Agonists and antagonists of bromix for the treatment of metabolic disorders
US20050288223A1 (en) * 2002-05-17 2005-12-29 Genset S.A. OBG3 Fragments Inhibiting The Conversion Of Active OBG3 Into Less Active OBG3 And Other Compositions For Treatment Of Metabolic Disorders
US7459433B2 (en) 2002-05-31 2008-12-02 Serono Genetics Institute, S.A. Homotrimeric extended OBG3 globular head and uses thereof
ES2574918T3 (es) * 2003-06-02 2016-06-23 Isis Innovation Limited Tratamiento de la fatiga muscular
EP1648952B1 (de) 2003-06-03 2018-03-07 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Nahrungszusätze und therapeutische zusammensetzungen, die (r)-3-hydroxybutyratderivate enthalten
US20070213263A1 (en) * 2003-10-09 2007-09-13 The Trustees Of Boston University Methods And Compositions Using Adiponectin For Treatment Of Cardiac Disorders And For Stimulation Of Angiogenesis
ES2365923T3 (es) 2004-03-31 2011-10-13 Kazuhisa Maeda Uso de adiponectina como marcador en la predicción de infección postoperatoria.
CN1740195B (zh) * 2005-04-15 2012-01-04 复旦大学 一种多肽gapM1及其制备方法
WO2007147563A1 (en) * 2006-06-20 2007-12-27 Laboratoires Serono S.A. Process for globular adiponectin production
DK2240017T3 (da) 2008-01-04 2019-06-17 Univ Oxford Innovation Ltd Ketonlegemer og ketonlegemsestere som blodlipid-sænkende midler
EP2088156A1 (de) 2008-02-08 2009-08-12 Institut Pasteur Verwendung von Adiponektin zur Diagnose und/oder Behandlung von Presbyakusis
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
GB201002983D0 (en) 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
EP2914251B1 (de) 2012-11-05 2019-08-21 The United States of America, as represented by The Secretary, Department of Health and Human Services Ketonkörper zum schutz von geweben vor beschädigung durch ionisierende strahlung
GB201304467D0 (en) 2013-03-12 2013-04-24 Tdeltas Ltd Compound for use in protecting skin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869330A (en) * 1995-06-05 1999-02-09 Whitehead Institute For Biomedical Research DNA encoding a novel serum protein produced exclusively in adipocytes
FR2767135B1 (fr) * 1997-08-06 2002-07-12 Genset Sa Recepteur complexe lsr, activite, clonage, et application au diagnostic, a la prevention et/ou au traitement de d'obesite et des risques ou complications associes
JP3538711B2 (ja) * 1997-10-29 2004-06-14 大塚製薬株式会社 平滑筋増殖抑制組成物、動脈硬化症診断方法及びそのキット

Also Published As

Publication number Publication date
WO2001051645A1 (en) 2001-07-19
AU785090B2 (en) 2006-09-14
JP2003519633A (ja) 2003-06-24
IL150554A (en) 2009-05-04
CY1108461T1 (el) 2014-04-09
CA2383136C (en) 2012-09-18
PT1248849E (pt) 2008-09-08
MXPA02006834A (es) 2005-07-01
DE60135439D1 (de) 2008-10-02
AU5789901A (en) 2001-07-24
JP4698914B2 (ja) 2011-06-08
CA2383136A1 (en) 2001-07-19
EP1248849A1 (de) 2002-10-16
BR0107626A (pt) 2002-10-15
DK1248849T3 (da) 2008-12-08
IL150554A0 (en) 2003-02-12
ES2312450T3 (es) 2009-03-01
EP1248849B1 (de) 2008-08-20

Similar Documents

Publication Publication Date Title
ATE405655T1 (de) Obg3 globularekopf und seine verwendungen zur reduzierung des körpersgewichtes
EA200300944A1 (ru) Ацилированные пиперидиновые производные в качестве агонистов рецептора-4 меланокортина
ATE306481T1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
ATE491421T1 (de) Vorrichtung zur behandlung des nasen-rachenraumes
ATE432052T1 (de) System zur behandlung von fettleibigkeit
ATE411021T1 (de) Überbrückte piperidinderivate als melanocortin- rezeptor-agonisten
ATE341327T1 (de) Acylierte piperidin-derivate als melanocortin-4- rezeptor-agonisten
ATE272944T1 (de) Zusammensetzung mit insektabschreckenden eigenschaften
WO2002002518A3 (en) Compounds to treat alzheimer's disease
ATE430193T1 (de) Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen
MXPA04000442A (es) Composicion de alimento para mascotas, para regular el peso corporal y evitar la obesidad y trastornos relacionados en mascotas.
WO2003010314A3 (en) Gmg-2 polynucleotides and polypeptides and uses thereof
ATE464378T1 (de) Verwendung des globulären kopfes von acrp30 zur verstärkung der zunahme von muskelmasse und - differenzierung
ATE359783T1 (de) Aroylpyrrolheteroeryl und methanole zur behandlung von störungen des zentralnervensystems
WO2003010197A3 (en) Gmg-1 polynucleotides and polypeptides and uses thereof
ATE380868T1 (de) Fragmente des humanen zn-alpha2-glykoproteins und deren verwendung in methoden zur behandlung der fettleibigkeit
ATE333452T1 (de) 4-(penylpiperidin-4-ylidenmethyl)benzamidderiva e und deren verwendung zur behandlung von schmerzen,angstzuständen oder erkrankungen des magen-darm- trakts
DE60110897D1 (de) Der duale inhibitor der cholesterylester und wachsester synthese avasimibe zur behandlung von erkrankungen des talgdrüse
WO2003009871A3 (en) Inhibitors of plasminogen activator inhibitor for decreasing body mass
WO2003033534A3 (en) Ngzipa, ngzipd, pgzipa, and pgzipd polynucleotides and polypeptides and uses thereof
DE60333917D1 (de) Homotrimerer, erweiterter globulärer kopf von obg3 und verwendungen davon
RU2002121567A (ru) Способ снижения уровня никеля в крови и молоке коров техногенной зоны
ATE286390T1 (de) Felabamat-derivate zur behandlung von neuropathischem schmerz
WO2003082915A3 (en) Xcrf polynucleotides and polypeptides and uses thereof
EP2177231A3 (de) Verwendung von Ziegenserum für veterinärmedizinische Behandlungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1248849

Country of ref document: EP